Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 416Lymphoma 406Lymphoma, Non-Hodgkin 344Leukemia, Lymphocytic, Chronic, B-Cell 313Lymphoma, Follicular 301Lymphoma, Mantle-Cell 226Lymphoma, B-Cell, Marginal Zone 161Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 85Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Hematologic Neoplasms 22Dendritic Cell Sarcoma, Interdigitating 22Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Hematologic Diseases 13Lymphoproliferative Disorders 12

Interventions

Oxaliplatin 2Leucovorin 2Fluorouracil 2dolutegravir 1acalabrutinib 1Yoga 1Tenofovir 1Rituximab 1Real-Time Polymerase Chain Reaction 1Pentoxifylline 1Massage 1Magnetic Resonance Spectroscopy 1Ketotifen 1Exercise 1Diffusion Tensor Imaging 1Bestrophins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuritis × Rituximab × Clear all
NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡